New Delhi: Indias pharmaceutical landscape is set to revolutionize the treatment of presbyopia with the introduction of a groundbreaking eye drop. The Drug Controller General of India (DCGI) has approved PresVu, an innovative eye drop designed to reduce the reliance on reading glasses for individuals suffering from presbyopia. Manufactured by Mumbai-based Entod Pharmaceuticals, PresVu will be available in pharmacies nationwide starting in October. It is priced at Rs 350 per bottle and available via prescription.What is PresbyopiaPresbyopia is a common, age-related vision condition where the eyes lens gradually loses its flexibility, making it difficult to focus on close objects. Typically affecting people over 40, presbyopia causes symptoms such as difficulty reading small print, the need to hold reading materials at arms length, and eye strain during close-up tasks. In India, nearly 45% of adults over 40 suffer from presbyopia, necessitating the use of reading glasses.A revolutionary treatment for PresbyopiaPresVu is touted as the first eye drop in India specifically formulated to treat presbyopia. The eye drops utilize advanced dynamic buffer technology, which enables them to adapt to the pH of the tears, ensuring consistent effectiveness and safety for long-term use. Besides eliminating the need for reading glasses, PresVu also offers the added benefit of lubricating the eyes, making it a comprehensive solution for those affected by this condition.This innovative product mirrors a similar formulation introduced in the US under the brand name Vuity, which was approved by the US Food and Drug Administration (US FDA) in 2022. Vuity remains the only FDA-approved eye drop for age-related blurry vision, and PresVu is poised to bring the same relief to millions in India.
